期刊文献+

枯草杆菌屎肠球菌二联活菌制剂对肝硬化大鼠肠道细菌易位的影响 被引量:8

Effects of Bacillus subtilis and Enterococcu faecim on bacterial translocation in cirrhotic rats
下载PDF
导出
摘要 目的:观察枯草杆菌屎肠球菌二联活菌制剂(商品名:美常安)对肝硬化大鼠肠道细菌易位的影响。方法:皮下注射40% CCl4橄榄油溶液诱导大鼠肝硬化模型,用枯草杆菌屎肠球菌二联活菌制剂治疗。采用改良鲎试验测定血清内毒素,无菌操作取肠系膜淋巴结、肝、脾组织分别进行细菌培养观察细菌易位情况。结果:枯草杆菌屎肠球菌二联活菌制剂组的内毒素血症阳性率为35.29%,明显低于肝硬化组的73.33%(P<0.05);细菌易位率为47.05%,明显低于肝硬化组的93.33%(P<0.05)。结论:枯草杆菌屎肠球菌二联活菌制剂能够降低肝硬化大鼠血清内毒素,减少肠道细菌易位发生的机会。 Objective:To evaluate the effects of Bacillus subtilis and Enterococcus faecim (Medilac-s) on bacterial translocation in cirrhotic rats.Method:The cirrhotic rats induced by subcutaneous 40% CCl4-olive oil solution were randomized to be treated with Bacillus subtilis (R-179) and Enterococcus faecim (R-026) or placebo for 14 days. At the end of treament,the plasma endotoxin was measured by limulus ameobocyte lysate (LAL) ,the mesenteric lymph nodes, tissue of spleen and liver were obtained. All samples were cultured in agar-blood plates. Results:The positive rate(35.29%) of plasma endotoxin in treatment group was significantly lower than that(73.33%) in model group(P< 0.05);the incidence(47. 05%) of bacterial translocation in treatment group was lower significantly than that(93.33%) in model group(P<0.05). Conclusion: The Bacillus subtilis (R-179) and Enterococcus faecim (R-026) could prevent the bacterial translocation and decrease the level of plasma endotoxin significantly in cirrhotic rats.
出处 《中国新药杂志》 CAS CSCD 北大核心 2004年第11期988-990,共3页 Chinese Journal of New Drugs
关键词 肝硬化大鼠 内毒素 细菌易位 微生态制剂 cirrhotic rat endotoxin bacterial translocation microecologics
  • 相关文献

参考文献11

  • 1[1]Kasravif B,Wang LQ,Molin G,et al.Bacterial translocation in acute liver injure induced by D-Galactosamine[J].Hepatology,1996,4(2):135-140.
  • 2[2]Ochs A.Spontaneous bacterial peritonitis:diagnosis and clinical course[A].Blum HE,Bode C,Bode JC,et al.Gut and the Liver.Falk Symposium 100[M].Freiburg:Falk Foundation,1997.29-31.
  • 3[3]Runyon BA.Fatal bacterial peritonitis:secondary to nonobstructive colonic dilatation (Ogilvie's syndrome) in cirrhosis ascites[J].J Clin Gastroenterol,1986,8(6):687-689.
  • 4[4]Bjarnason I,Macpherson A,Hollander D.Intestinal permeability:an overview [J].Gastroenterology,1995,108(5):1566-1581.
  • 5[5]Vander Hulst RWJ,Von Meyenfeldt MF,Van Kreel BK,et al.Gut permeability,intestinal morphology,and nutrition depletion[J].Nutrition,1998,14(2):1-4.
  • 6[6]Parlesak A,Schafer C,Schutz T,et al.Increased intestinal permeability to macromoleculeas and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol induced liver disease[J].J Hepatol,2000,32(5):742-747.
  • 7赵军,施志国,黎沾良,盛志勇.创伤后营养方式与肠屏障功能——(文献综述)[J].国外医学(外科学分册),1992,19(1):1-4. 被引量:9
  • 8[8]Lichtman SM.Bacterial translocation in humans[J].J Pediatr Gastroenterol Nutr,2001,33(1):1-10.
  • 9周殿元.肠道菌群和内毒素易位及其防治[J].胃肠病学,2003,8(1):3-5. 被引量:14
  • 10[11]Guarner C,Runyon B,Young S,et al.Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites[J].J Hepatol,1997,26(6):1372-1378.

二级参考文献5

  • 1杨景云.微生态调节剂[A].见:杨景云主编.医用微生态学[C].北京:中国医药科技出版社,1997.109~124.
  • 2胡森 姚咏明 见:盛志勇 胡森主编.MODS的发病假说[A].见:盛志勇,胡森主编.多器官功能障碍综合征[C].北京:科学技术出版社,1999.29~49.
  • 3郭传勇.菌群失调症[A].见:张达荣主编.消化系疾病与微生态[C].上海:上海科学技术出版社,2001.89~130.
  • 4李兰娟,黄建荣,陈月美,扬芊,陈亚岗,马伟杭,陈智,傅素珍.人工肝支持系统治疗重型肝炎应用研究[J].中华传染病杂志,1999,17(4):228-230. 被引量:200
  • 5吴仲文,李兰娟,马伟杭,俞云松,陈亚岗.肠道微生物定植抗力的新指标—— B/E值[J].浙江预防医学,2000,12(7):4-5. 被引量:77

共引文献42

同被引文献80

引证文献8

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部